Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mitoguazone (Methyl-GAG) 是一种可透过血脑屏障的选择性的 S-腺苷-蛋氨酸脱羧酶 (S-adenosyl-methionine decarboxylase) 抑制剂,可破坏多胺的生物合成。Mitoguazone 是一种具有抗肿瘤活性的合成多羰基衍生物,可抑制 HIV DNA 整合到单核细胞和巨噬细胞中的细胞 DNA 中,诱导细胞凋亡 (apoptosis)。Mitoguazone 具可用于预防急性白血病,霍奇金淋巴瘤和非霍奇金淋巴瘤。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 720 | 现货 | ||
5 mg | ¥ 1,230 | 5日内发货 | ||
10 mg | ¥ 1,830 | 5日内发货 | ||
25 mg | ¥ 3,370 | 5日内发货 | ||
50 mg | ¥ 4,970 | 5日内发货 | ||
100 mg | ¥ 6,860 | 6-8周 | ||
500 mg | ¥ 13,800 | 5日内发货 |
产品描述 | Mitoguazone (Methyl-GAG) is a selective S-adenosyl-methionine decarboxylase inhibitor that penetrates the blood-brain barrier and disrupts polyamine biosynthesis. Mitoguazone is a synthetic polycarbonyl derivative with anti-tumor activity that inhibits the integration of HIV DNA into cellular DNA in monocytes and macrophages, inducing apoptosis. Mitoguazone can be used to prevent acute leukemia, Hodgkin lymphoma and non-Hodgkin lymphoma. |
体外活性 |
At concentrations as low as 0.5 μg/mL, Mitoguazone competitively inhibits spermidine synthesis in lymphocytes. At levels of 30 μg/mL or higher, it inhibits protein synthesis and mitochondrial respiration[5]. The ability of Mitoguazone to induce apoptosis by inhibiting the polyamine pathway was evaluated in three Burkitt lymphoma cell lines (Raji, Ramos, and Daudi) and a prostate cancer cell line (MPC 3). Mitoguazone induces apoptosis in a concentration- and time-dependent manner in all tested human cancer cell lines, and triggers p53-independent programmed cell death in the human breast cancer MCF7 cell line[2]. |
体内活性 | The impact of different stages of leukemia (P388) on the pharmacokinetics of the anti-tumor drug Mitoguazone was investigated in mice. Regardless of the tumor stage under study, there was a slight reduction in the total clearance rate of Mitoguazone, reflecting a moderate increase in the AUC in the serum of leukemia-afflicted animals. Additionally, at the late tumor stage, the drug levels in the kidneys, liver, spleen, and serum were somewhat higher compared to early-stage leukemia, and were elevated to a certain extent compared to the tumor-free control[1]. |
别名 | MGBG, Methyl-GAG |
分子量 | 184.2 |
分子式 | C5H12N8 |
CAS No. | 459-86-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 50 mg/mL (271.44 mM), when pH is adjusted to 9 with HCl. Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O | 1 mM | 5.4289 mL | 27.1444 mL | 54.2888 mL | 135.722 mL |
5 mM | 1.0858 mL | 5.4289 mL | 10.8578 mL | 27.1444 mL | |
10 mM | 0.5429 mL | 2.7144 mL | 5.4289 mL | 13.5722 mL | |
20 mM | 0.2714 mL | 1.3572 mL | 2.7144 mL | 6.7861 mL | |
50 mM | 0.1086 mL | 0.5429 mL | 1.0858 mL | 2.7144 mL | |
100 mM | 0.0543 mL | 0.2714 mL | 0.5429 mL | 1.3572 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Mitoguazone 459-86-9 Apoptosis Microbiology/Virology Proteases/Proteasome HIV Protease MGBG Methyl-GAG Inhibitor inhibitor inhibit